BIRMINGHAM, Ala., Jan. 11, 2023 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will report results for its fourth quarter ended Dec. 31, 2022, after the market closes on Feb. 7, 2023. The Company will host an investor conference call at 10 a.m. ET on Feb. 8, 2023, to discuss its results.
The conference call may be accessed by dialing 800-245-3047 and giving the conference ID EHCQ422. International callers should dial 203-518-9765 and give the same conference ID. Please call approximately 10 minutes before the start of the call to ensure you are connected.
A live webcast of the conference call and an online replay of the conference call can be found on the Company's investor website at https://investor.encompasshealth.com.
Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 153 hospitals in 36 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's 100 Best Companies to Work For and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
Media Contact:
Casey Winger | 205 970-5912
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
Mark Miller | 205 970-5860
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$96.89 |
| Daily Change: | 0.56 0.58 |
| Daily Volume: | 238,444 |
| Market Cap: | US$9.750B |
August 05, 2024 July 30, 2024 July 08, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
